Loss of the matriptase inhibitor HAI-2 during prostate cancer progression

Prostate

Volumn 70, Issue 13, 2010, Pages 1422-1428

  Bergum, Christopher ^a   List, Karin ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HAI 2; Matriptase; Prostate cancer; Tumor suppressor

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; ULINASTATIN; MEMBRANE PROTEIN; SPINT2 PROTEIN, HUMAN;

ANTIBODY DETECTION; ARTICLE; CANCER GROWTH; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; CARCINOMA; DISEASE COURSE; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TISSUE MICROARRAY;

CARCINOMA; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; STATISTICS, NONPARAMETRIC; TISSUE ARRAY ANALYSIS;

EID: 77956630130     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21177     Document Type: Article

References (46)

1. Kawaguchi T, Qin L, Shimomura T, Kondo J, Matsumoto K, Denda K, Kitamura N,. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 27558 -27564.
2. Marlor CW, Delaria KA, Davis G, Muller DK, Greve JM, Tamburini PP,. Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains. J Biol Chem 1997; 272: 12202 -12208.
3. Dong W, Chen X, Xie J, Sun P, Wu Y,. Epigenetic inactivation and tumor suppressor activity of HAI-2/SPINT2 in gastric cancer. Int J Cancer 2010; [Epub ahead of print].
4. Tung EK, Wong CM, Yau TO, Lee JM, Ching YP, Ng IO,. HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions. Int J Cancer 2009; 124 (8): 1811 -1819.
5. Kongkham PN, Northcott PA, Ra YS, Nakahara Y, Mainprize TG, Croul SE, Smith CA, Taylor MD, Rutka JT,. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res 2008; 68 (23): 9945 -9953.
6. Hamasuna R, Kataoka H, Meng JY, Itoh H, Moriyama T, Wakisaka S, Koono M,. Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: Implication for anti-invasive role of HAI-2/PB in glioblastoma cells. Int J Cancer 2001; 93 (3): 339 -345.
7. Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, Osada Y, Kataoka H,. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci 2007; 98 (4): 491 -498.
8. Nakamura K, Abarzua F, Kodama J, Hongo A, Nasu Y, Kumon H, Hiramatsu Y,. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer. Int J Oncol 2009; 34 (2): 345 -353.
9. Heinz-Erian P, Müller T, Krabichler B, Schranz M, Becker C, Rüschendorf F, Nürnberg P, Rossier B, Vujic M, Booth IW, Holmberg C, Wijmenga C, Grigelioniene G, Kneepkens CM, Rosipal S, Mistrik M, Kappler M, Michaud L, Dóczy LC, Siu VM, Krantz M, Zoller H, Utermann G, Janecke AR,. Mutations in SPINT2 cause a syndromic form of congenital sodium diarrhea. Am J Hum Genet 2009; 84 (2): 188 -196.
10. Alef T, Torres S, Hausser I, Metze D, Tursen U, Lestringant G, Hennies HC,. Ichthyosis, follicular atrophoderma, and hypotrichosis caused by mutations in ST14 is associated with impaired profilaggrin processing. J Invest Dermatol 2008; 129: 862 -869.
11. Basel-Vanagaite L, Attia R, Ishida-Yamamoto A, Rainshtein L, Ben Amitai D, Lurie R, Pasmanik-Chor M, Indelman M, Zvulunov A, Saban S, Magal N, Sprecher E, Shohat M,. Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase Am J Hum Genet 2007; 80 (3): 467 -477.
12. List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W, Engelholm LH, Behrendt N, Bugge TH,. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 2002; 21: 3765 -3779.
13. List K, Szabo R, Molinolo A, Nielsen BS, Bugge TH,. Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am J Pathol 2006; 168: 1513 -1525.
14. List K, Kosa P, Szabo R, Bey AL, Wang CB, Molinolo A, Bugge TH,. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol 2009; 175 (4): 1453 -1463.
15. Buzza MS, Netzel-Arnett S, Shea-Donohue T, Zhao A, Lin CY, List K, Szabo R, Fasano A, Bugge TH, Antalis TM,. The membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci USA 2010; 107 (9): 4200 -4205.
16. List K,. Matriptase: A culprit in cancer? Future Oncol 2009; 5 (1): 97 -104.
17. Bugge TH, List K, Szabo R,. Matriptase-dependent cell surface proteolysis in epithelial development and pathogenesis. Front Biosci 2007; 12: 5060 -5070.
18. Bugge TH, Antalis TM, Wu Q,. Type II transmembrane serine proteases. J Biol Chem 2009; 284 (35): 23177 -23181.
19. Uhland K,. Matriptase and its putative role in cancer. Cell Mol Life Sci 2006; 63 (24): 2968 -2978. Review.
20. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T, Burke B, Nielsen BS, Gutkind JS, Bugge TH,. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes rasmediated malignant transformation. Genes Dev 2005; 19: 1934 -1950.
21. Szabo R, Hobson JP, List K, Molinolo A, Lin CY, Bugge TH,. Potent inhibition and global co-localization implicate the transmembrane kunitz-type serine protease inhibitor hai-2 in the regulation of epithelial matriptase activity. J Biol Chem 2008; 283: 29495 -29504.
22. Itoh H, Kataoka H, Tomita M, Hamasuna R, Nawa Y, Kitamura N, Koono M,. Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa. Am J Physiol Gastrointest Liver Physiol 2000; 278 (4): G635 -G643.
23. Yamauchi M, Itoh H, Naganuma S, Koono M, Hasui Y, Osada Y, Kataoka H,. Expression of hepatocyte growth factor activator inhibitor type 2 (HAI-2) in human testis: Identification of a distinct transcription start site for the HAI-2 gene in testis. Biol Chem 2002; 383 (12): 1953 -1957.
24. Yamauchi M, Kataoka H, Itoh H, Seguchi T, Hasui Y, Osada Y,. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma. J Urol 2004; 171 (2 Pt 1): 890 -896.
25. Kilpatrick LM, Harris RL, Owen KA, Bass R, Ghorayeb C, Bar-Or A, Ellis V,. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood 2006; 108: 2616 -2623.
26. Szabo R, Hobson JP, Christoph K, Kosa P, List K, Bugge TH,. Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice. Development 2009; 136 (15): 2653 -2663.
27. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H,. A novel biomarker for staging human prostate adenocarcinoma: Overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 2006; 15 (2): 217 -227.
28. Riddick ACP, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY, Edwards DR,. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 2005; 92: 2171 -2180.
29. Sanders AJ, Parr C, Davies G, Martin TA, Lane J, Mason MD, Jiang WG,. Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo. J Exp Ther Oncol 2006; 6: 39 -48.
30. Förbs D, Thiel S, Stella MC, Stürzebecher A, Schweinitz A, Steinmetzer T, Stürzebecher J, Uhland K,. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol 2005; 27: 1061 -1070.
31. Wang JK, Lee MS, Tseng IC, Chou FP, Chen YW, Fulton A, Lee HS, Chen CJ, Johnson MD, Lin CY,. Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition. Am J Physiol Cell Physiol 2009; 297 (2): C459 -C470.
32. Nagakawa O, Yamagishi T, Akashi T, Nagaike K, Fuse H,. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer. Prostate 2006; 66 (5): 447 -452.
33. Delaria KA, Muller DK, Marlor CW, Brown JE, Das RC, Roczniak SO, Tamburini PP,. Characterization of placental bikunin, a novel human serine protease inhibitor. J Biol Chem 1997; 272: 12209 -12214.
34. Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ,. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J 2005; 390: 125 -136.
35. Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P,. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 2005; 579: 1945 -1950.
36. Qin L, Denda K, Shimomura T, Kawaguchi T, Kitamura N,. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 2. FEBS Lett 1998; 436: 111 -114.
37. Szabo R, Molinolo A, List K, Bugge TH,. Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene 2007; 26 (11): 1546 -1556.
38. Szabo R, Kosa P, List K, Bugge TH,. Loss of matriptase suppression underlies Spint1 mutation-associated ichthyosis and postnatal lethality. Am J Pathol 2009; 174 (6): 2015 -2022.
39. Warren M, Twohig M, Pier T, Eickhoff J, Lin CY, Jarrard D, Huang W,. Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: A tissue microarray and automated quantitative analysis. Appl Immunohistochem Mol Morphol 2009; 17 (1): 23 -30.
40. Kiyomiya K, Lee MS, Tseng IC, Zuo H, Barndt RJ, Johnson MD, Dickson RB, Lin CY,. Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. Am J Physiol Cell Physiol 2006; 291 (1): C40 -C49.
41. Takeuchi T, Shuman MA, Craik CS,. Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 1999; 96 (20): 11054 -11061.
42. Owen KA, Qiu D, Alves J, Schumacher AM, Kilpatrick LM, Li J, Harris JL, Ellis V,. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochim Biophys Acta 2007; 1773 (7): 1133 -1140.
43. Chen M, Fu YY, Lin CY, Chen LM, Chai KX,. Prostasin induces protease-dependent and independent molecular changes in the human prostate carcinoma cell line PC-3. Biochim Biophys Acta 2007; 1773 (7): 1133 -1140.
44. Parr C, Jiang WG,. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int J Oncol 2001; 19: 857 -863.
45. Parr C, Watkins G, Mansel RE, Jiang WG,. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004; 10 (1 Pt 1): 202 -211.
46. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V,. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004; 6 (2): 185 -195.